CARSGEN THERAPEUTICS CO., LTD.;SHANGHAI CANCER INSTITUTE
发明人:
Zonghai LI,Xingliang GUO
申请号：
US16645247
公开号：
US20200261502A1
申请日:
2018.09.07
申请国别(地区):
US
年份:
2020
代理人:
摘要：
Provided are a genetically engineered T cell and a pharmaceutical composition using the same. The T cell has an endogenous T cell receptor (TCR) that is inactivated or inactive, comprises encoding of an exogenous receptor bindable to a target antigen, and contains an open reading frame regulated by the exogenous receptor. When the exogenous receptor binds to the target antigen, expression of the open reading frame can be initiated. The T cell has a killing effect on tumor cells and has reduced side effects and enhanced safety.
